|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
3675 Market St, Suite 200, Philadelphia, Pennsylvania 19104, US
|
|
Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.
Verismo Therapeutic’s core technology is built upon CARs that are uniquely engineered to more realistically reflect the natural multichain design of killer immunoglobulin-like receptors (KIRs), an important family of immunologic receptors used by T cells and NK cells.
Preclinical studies show that SynKIR™-T cells, created by introducing these KIR-based CARs (KIR-CARs) into T cells, more effectively eliminate aggressive tumors in vivo when compared with T cells bearing traditional 2nd generation CAR designs found in current FDA approved CAR-T cell therapies.
|
Verismo Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Verismo Therapeutics email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Verismo Therapeutics customer service number call here 215-989-4225. To contact Verismo Therapeutics customer service number in your country click here to find.
Bryan Kim is the CEO of Verismo Therapeutics. To contact Bryan Kim email at [email protected] or [email protected]. Or you may call +1.8568668611
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.